drugset / Trial / NCT06951503
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
RandomizedParallel-groupTriple-blindTreatment
Summary
This trial is a Phase III study. The purpose of this study is to evaluate the efficacy and safety of AK112 and chemotherapy versus bevacizumab and chemotherapy for the first-line treatment of metastatic colorectal cancer.
Timeline
- Start
- 2025-05-27
- Primary completion
- 2027-01-13
- Completion
- 2029-01-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bevacizumab | Monoclonal antibody | — | Intravenous |
| Subject | Ivonescimab | Monoclonal antibody | — | Intravenous |
| Background | Irinotecan | Small molecule | — | Intravenous |
| Background | Leucovorin | Small molecule | — | Intravenous |
| Background | Oxaliplatin | Small molecule | — | Intravenous |
| Background | fluorouracil | Small molecule | — | Intravenous |